NASDAQ: CAICaris Life Sciences Inc Stock
$32.58-0.85 (-2.54%)
Updated Sep 19, 2025
CAI Price
$32.58
Fair Value Price
N/A
Market Cap
$9.16B
52 Week Low
$25.42
52 Week High
$42.50
P/E
N/A
P/B
20.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.11
Operating Cash Flow
N/A
Beta
1.19
Next Earnings
Nov 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CAI Overview
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
CAI
Ranked#37 of 45
Ranked#37 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.63 | A | |
| $656.16 | A | |
| $155.39 | B |
Be the first to know about important CAI news, forecast changes, insider trades & much more!
CAI News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAI is poor value based on its book value relative to its share price (20.23x), compared to the US Diagnostics & Research industry average (3.81x)
P/B vs Industry Valuation
CAI's short-term assets ($833.32M) exceed its short-term liabilities ($90.18M)
Short-term Liabilities Financials
CAI's short-term assets ($833.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CAI due diligence checks available for Premium users.
Valuation
CAI fair value
Fair Value of CAI stock based on Discounted Cash Flow (DCF)
Price
$32.58
Fair Value
-$38.01
Undervalued by
185.71%
CAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.23x
Industry
3.81x
CAI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAI's financial health
Profit margin
Revenue
$181.4M
Net Income
-$71.8M
Profit Margin
-285.1%
Assets to liabilities
Assets
$955.1M
Liabilities
$502.2M
Debt to equity
1.11
CAI's short-term assets ($833.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAI's short-term assets ($833.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.3M
Investing
-$1.4M
Financing
$681.4M
CAI vs Diagnostic & Research Stocks
Caris Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.